Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Post by herbeapuceon Jul 26, 2019 3:08pm

171 Views

Post# 29965240

Next question: when will EC give the final decision ?

Hi everyone.

Quote: """ This positive opinion will now be taken into consideration by the European Commission (EC) which will issue a final decision in the near future. """

IYO how much time before TH get the formal approval , ( I prefer that to "" final decision "" hopefully )

what is your best educated guess plz ?

thank you
stef

Bullboard Posts

Visionstate set to leverage success in the U.S. market